CER Daily Newsfeed

MFN Drug Pricing: Risks to Access, Affordability, and Innovation in Health Care

(7/16, Pearl Steinzor, Adam Colborn, JD, The American Journal of Managed Care) reports “...During an opinion webinar by The American Journal of Managed Care® (AJMC®), panelists explored the implications of Trump’s 2025 executive order on MFN drug pricing, examining its potential to reshape drug costs, access, and the role of intermediaries like PBMs. Moderated by Ryan Haumschild, PharmD, MBA, MS, CPEL, the discussion included insights from John O’Brien, PharmD, MPH; Kathy Oubre, MS; and Justin Favaro, MD, PhD. Although the MFN order aims to align US drug prices with those in comparable countries and targets brand-name drugs without competition, experts expressed concern about its vague policy framework, legal uncertainties, and potential consequences for provider reimbursement and patient care.” Full

Video: The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference

(7/17, Prescription for Better Access, YouTube) “At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.” View Video

Video: Toward a US HTA? Examining the IRA’s Emerging Role

(7/17, The Evidence Base) “...At ISPOR 2025, Priti Jhingran and Tijana Ignjatovic from Genesis Research Group explored this topic in their session, ‘Is IRA Becoming America’s HTA?’ In this interview, we speak with Priti and Tijana to dive deeper into their insights and discuss what the IRA might mean for future pricing and access strategies.” View Video

Maximize Real World Data Value with Panalgo on AWS

(7/17, Ragib Ahsan, Erik Maul, Eric Girouard, April Duddy, and Srini Raghavan, Amazon AWS Blog) comments “...As healthcare organizations continue to invest heavily in RWD, the ability to quickly and securely derive insights becomes a critical competitive advantage...The evolving landscape of healthcare analytics demands solutions that can turn vast amounts of raw data into actionable insights efficiently. Panalgo’s IHD Cloud, with its advanced capabilities deployed directly within customers’ secure environments, is positioned to meet this need, driving better patient outcomes and more efficient healthcare delivery.” Full

Britain's Life Sciences Plan Gets Mixed Reception from Pharma Industry

(7/16, Alistair Smout, Reuters) reports “...While there was still an impasse on drug pricing, the government released the sector plan, which noted ‘intense competition for investment’ and pledged to reform the regulation of medicine so more drugs get to the state-run National Health Service quicker. However, the Association of the British Pharmaceutical Industry (ABPI) said the plan was ‘not enough to turn around the UK's decline’ and Britain still needed to address ‘the long-term disinvestment in innovative medicines.’ ‘For too long, the UK has sought to be the place where innovation happens, but not the place where it is used,’ said Richard Torbett, chief executive of the ABPI.” Subscription Required

UK: Novartis’ Kisqali Recommended by NICE to Treat Broad Early Breast Cancer Population

(7/17, Emily Kimber, PMLiVE) reports “Novartis’ Kisqali (ribociclib) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broad population of early breast cancer patients. The health technology assessment agency has recommended in final draft guidance that the drug be used on the NHS in combination with an aromatase inhibitor as an additional treatment option for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.” Full